Hemoglobin modulation affects physiology and patient reported outcomes in anemic and non-anemic subjects: An umbrella review

Autor: Tonino, R.P.B., Zwaginga, L.M., Schipperus, M.R., Zwaginga, J.J.

Publikováno v: Frontiers in Physiology, 14. FRONTIERS MEDIA SA

Background: An abnormal hemoglobin concentration has a substantial effect on a person’s quality of life and physiology. Lack of tools that effectively evaluate hemoglobin-related outcomes leads to uncertainty regarding optimal hemoglobin levels, tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a382810535348d4d4d7a0c7c4370d46

Platelets in ITP: cictims in charge of their own fate? Cells, 10(11), 3235

Autor: Nelson, V.S., Jolink, A.T.C., Amini, S.N., Zwaginga, J.J., Netelenbos, T., Semple, J.W., Porcelijn, L., Haas, M. de, Schipperus, M.R., Kapur, R.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______202::52a77b22c4fbf7645c50044fe155c656
https://hdl.handle.net/1887/3627412

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Storage medium of platelet transfusions and the risk of transfusion-transmitted bacterial infections

Autor: Kreuger, A.L., Middelburg, R.A., Kerkhoffs, J.L.H., Schipperus, M.R., Wiersum-Osselton, J.C., Bom, J.G. van der

Publikováno v: Transfusion, 57(3), 657-660

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::63374b30f1b14b27f410ed05492c799b
http://hdl.handle.net/1887/114457

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Autor: Zwaginga, J.J., Holt, B. van der, Boekhorst, P.A. te, Biemond, B.J., Levin, M.D., Griend, R. van der, Brand, A., Zweegman, S., Pruijt, H.F.M., Novotny, V.M.J., Vreugdenhil, A., Groot, M.R. de, Weerdt, O. de, Pampus, E.C.M. van, Maanen-Lamme, T.M. van, Wittebol, S., Schipperus, M.R., Silbermann, M.H., Huijgens, P.C., Luten, M., Hollestein, R., Brakenhoff, J.A.C., Schrama, J.G., Valster, F.A.A., Velders, G.A., Koene, H.R., Dutch HOVON 64 Study Grp

Publikováno v: Zwaginga, JJ, van der Holt, B, te Boekhorst, P A, Biemond, B J, Levin, M D, van der Griend, R, Brand, A, Zweegman, S, Pruijt, H F M, Novotny, V M J, Vreugdenhil, A, de Groot, M R, de Weerdt, O, van Pampus, E C M, van Maanen-Lamme, T M, Wittebol, S, Schipperus, M R, Silbermann, M H, Huijgens, P C, Luten, M, Hollestein, R, Brakenhoff, J A C, Schrama, J G, Valster, F A A, Velders, G A & Koene, H R 2015, ' Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients ', Haematologica, vol. 100, no. 3, pp. E90-E92 . https://doi.org/10.3324/haematol.2014.110213
Haematologica, 100, e90-2
Haematologica, 100, 3, pp. e90-2
Haematologica-the Hematology Journal, 100(3), E90-E92. Ferrata Storti Foundation
Haematologica, 100(3), E90-E92
Haematologica, 100(3), E90-E92. Ferrata Storti Foundation
Haematologica, 100(3), e90-e92. Ferrata Storti Foundation

The overall short-term treatment efficacy of rituximab (R) in immune thrombocytopenia (ITP) is reported to be approximately 58%.[1][1],[2][2] With four once-weekly 375 mg/m2 doses, responses of 31% after two years,[2][2] and 21% after five years[2][2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf58d4b2021439809e6420cdc02f1765
https://doi.org/10.3324/haematol.2014.110213